

EMA/216887/2019

European Medicines Agency decision P/0173/2019

of 15 May 2019

on the acceptance of a modification of an agreed paediatric investigation plan for imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A) (EMEA-001809-PIP01-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0173/2019

of 15 May 2019

on the acceptance of a modification of an agreed paediatric investigation plan for imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A) (EMA-001809-PIP01-15-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0163/2016 issued on 15 June 2016,

Having regard to the application submitted by Merck Sharp & Dohme (Europe), Inc. on 13 December 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 March 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A), powder for solution for infusion, parenteral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Merck Sharp & Dohme (Europe), Inc., Clos du Lynx/Lynx Binnenhof, 5, 1200 - Brussels, Belgium.

EMA/916595/2019
Amsterdam, 29 March 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001809-PIP01-15-M01

Scope of the application

Active substance(s):

Imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A)

Condition(s):

Treatment of Gram-negative bacterial infections

Pharmaceutical form(s):

Powder for solution for infusion

Route(s) of administration:

Parenteral use

Name/corporate name of the PIP applicant:

Merck Sharp & Dohme (Europe), Inc.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme (Europe), Inc. submitted to the European Medicines Agency on 13 December 2018 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0163/2016 issued on 15 June 2016.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 29 January 2019.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of Gram-negative bacterial infections

2.1.1. Indication(s) targeted by the PIP

Treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)

Treatment of serious bacterial infections including HABP, VABP, complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI) caused by known or clinically suspected carbapenem-resistant pathogens in patients with limited treatment options

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	2	Study 1 Dose range-finding juvenile toxicity study Study 2 Definitive juvenile toxicity study

Clinical studies	2	Study 3 Open-label study to evaluate the pharmacokinetics, safety and tolerability of a single dose of imipenem (monohydrate) / cilastatin (sodium) / relebactam (MK-7655A) and to identify the appropriate dose of MK-7655A in children from birth to less than 18 years of age with Gram-negative bacterial infections Study 4 Open-label, randomised, active-controlled trial to evaluate safety, tolerability and efficacy of MK-7655A in children from birth to less than 18 years of age with Gram-negative bacterial infections Study 5 <i>Deleted during procedure EMEA-001809-PIP01-15-M01</i>
Extrapolation, modelling and simulation studies	2	Study 6 Modelling and simulation study to select doses in children from birth to less than 18 years of age with Gram-negative bacterial infections Study 7 Extrapolation study to evaluate the use of MK-7655A in the proposed paediatric indications in children from birth to less than 18 years of age with serious Gram-negative bacterial infections
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes